Key Words: NEUROMUSCULAR RELAXANTS: a1curonium, suxamethonium; ANTAGONISTS: neostigmine; MONITORING: electromyography Suxamethonium is often used for intubation prior to the use of a non depolarising muscle relaxant. This study was undertaken to determine whether the prior use of suxamethonium 1.0 mg/kg influenced the degree of paralysis induced by a1curonium and its reversibility with neostigmine. There were three groups of twenty patients, two of whom received a1curonium 0.3 mg/kg, one group having also received suxamethonium 1.0 mglkg. The third group was given a1curonium 0.2 mg/kg after suxamethonium, to test the hypothesis that a full dose of a1curonium was not required after suxamethonium.
METHODS
The study was conducted as part of the monitoring of patients aged 2-15 years, mostly undergoing routine procedures such as tonsillectomy, adenoidectomy and associated operations. The children were not receiving any medication that interfered with the neuromuscular junction.
Three randomised groups of patients each with two subgroups were studied: 1 a. suxamethonium 1.0 mg/kg, a1curonium 0.2 mg/ kg, neostigmine 25 Jlglkg; lb. suxamethonium 1.0 mg/kg, alcuronium 0.2 mglkg, neostigmine 50 Jlg/kg; 2a. suxamethonium 1.0 mg/kg, alcuronium 0.3 mg/kg, neostigmine 25 Jlg/kg; 2b. suxamethonium 1.0 mg/kg, alcuronium 0.3 mg/kg, neostigmine 50 Jlg/kg; 3a. no suxamethonium, a1curonium 0.3 mg/kg, neostigmine 25 Jlg/kg; 3b. no suxamethonium, alcuronium 0.3 mg/kg, neostigmine 50 Jlg/kg. The patients were premedicated with intramuscular papaveretum and hyoscine or oral chloral hydrate or diazepam followed by intraoperative morphine. They were anaesthetised with thiopentone (about 5 mg/kg) and ventilated with oxygen and nitrous oxide only, while electromyograph (EMG) electrodes were attached -two stimulating electrodes over the ulnar nerve 1~~~~----------~~~~~----FIGURE I.-Typical EMG pattern after suxamethonium is given and then, after 50% recovery in twitch height, the response to a1curonium. Reversal shows two lines representing the recovery following 50 and 25 l1g1kg neostigmine respectively. The five measurements made are illustrated.
at the wrist, a neutral electrode on the forearm and recording electrodes over the adductor pollicis muscle and the base of the middle finger. The ulnar nerve was stimulated supramaximally at 0.1 Hz. Suxamethonium 1.0 mg/kg was administered to groups 1 and 2. When 50% recovery of the twitch height was reached, alcuronium 0.2 or 0.3 mg/kg was given (Figure 1 ). In group 3, alcuronium 0.3 mg/kg only was administered. When the operation was completed, neostigmine 25 or 50 Ilg/kg was given and the rate of reversal of neuromuscular block from 20 to 50% of EMG twitch height was measured.
The groups receiving 25 Ilg/kg neostigmine (la, 2a, 3a) were compared for rate of twitch height recovery from 20 to 50%, with those receiving 50 Ilg/kg neostigmine (1 b, 2b, 3b).
The following criteria had to be satisfied, otherwise the patient was rejected from the study and replaced by an additional patient: (a) the time from alcuronium administration. to reversal with neostigmine was less than 40 minutes; (b) no additional increments of a1curonium were given during the study; (c) twitch height at the time of reversal was less than 25% of control. In the comparison of time to recover from 20 to 50% twitch height, in the few patients who had already recovered to between 20 to 25%, the slope of the recovery line from the time of injection was extrapolated back to 20% for the purpose of measurement. -The results were plotted on a semi log graph and then curves were fitted using linear regression smoothing. This is a graph derived from the recovery rate results which illustrates the mean reversal times from 20 to 50% twitch height following 25 and 50 l1g/kg neostigmine when given at different levels of neuromuscular block. It can be seen that reversal is twice as long when the smaller dose is used. Table 1 shows the mean age and range of ages of the children in each group. Table 2 shows that alcuronium 0.2 mg/kg produced significantly less neuromuscular block with a slower onset than following 0.3 mg/kg.
Although the degree of neuromuscular block was calculated to be statistically significantly greater when alcuronium 0.3 mg/kg was given after suxamethonium than when administered alone, the difference was between means of93.1 % and 95.5%. This is clinically insignificant and within the margin of error in the method of measurement (± 1-2%). The mean time to reach maximum block following alcuronium was similar in groups 2 and 3. Some patients (14%) had an onset time following alcuronium to maximum block of over ten minutes. This occurred in both groups, whether alcuronium was preceded by suxamethonium or not. Although the alcuronium was given when 50% recovery from suxamethonium had been achieved, there was usually continued recovery before the onset of the non-depolarising block (Figure 2 ). Table 3 shows that the mean time from injection to reversal was shorter when 0.2 mg/kg alcuronium was used and that the degree of neuromuscular block was less than in groups 2 and 3 (alcuronium 0.3 mglkg). Recovery rate, measured between 20 and 50% recovery, was longer in each group following neostigmine 25 ~g/kg than following 50 ~g/kg but the difference reached statistical significance only in group 2. The difference in recovery rate following the two neostigmine doses was least when suxamethonium was not used. There was no significant difference in the rate of recovery between group 2 and group 3, i.e. whether alcuronium was preceded or not by suxamethonium (Table 3) . Figure 3 shows the time taken for twitch height to recover from 20-50% against the level of neuromuscular block present when the neostigmine was administered. It demonstrates that the rate of recovery is more rapid with the larger dose of neostigmine and that, at a given percentage of neuromuscular block, doubling the neostigmine dose from 25 to 50 ~g/kg approximately halves the recovery time. At deep levels of neuromuscular block, recovery following 25 ~g/kg is so much slower that the dose of 50 ~glkg neostigmine is needed. There were considerable methodological differences in these studies, including the use of very small doses in several of them.!,3-6 Most investigators waited until full recovery from suxamethonium before the nondepolarising relaxant was given. Katz et al. showed no difference when doxacurium was given at either 10% or 95% recovery. 8 In some cases the second drug was given up to 30 minutes 3 and one hour 2 after the suxamethonium.
Walts and Dillon used d-tubocurarine 4 mg and 8 mg/m2 body surface area. 9 With the lower dose, they found less blockade from d-tubocurarine when it was given at 10% recovery than when it was given alone. However, there was no difference at the higher dose, whether it was given alone, at 10% or after full recovery.
In clinical practice, suxamethonium is frequently used in a dose of 1.0 mg/kg and many anaesthetists wait for initial signs of return of respiration before giving the nondepolarising relaxant. Our study aimed to determine whether a smaller dose of alcuronium (0.2 mg/kg) following suxamethonium produced comparable relaxation to our usual dose of alcuronium (0.3 mg/kg), given alone. The results show that this is not the case. The ED95. of alcuronium has since been determined in patients in this age group to be 270 llg/kg.1O Alcuronium was given at 50% recovery from suxamethonium, a level a little above that where alcuronium would commonly be given after suxamethonium in clinical practice. This was chosen as a standard level where respiratory efforts will have begun in all patients, as this usually occurs between 15 and 30% twitch height.
Our study also showed that recovery was more rapid when the larger dose of neostigmine was used for reversal. If recovery was already over 25%, the smaller dose (25 Ilg/kg) produced satisfactory early reversal of the neuromuscular block. This finding supports the concept that the deeper the block, the bigger the dose of neostigmine needed for prompt reversal.
In conclusion, our results demonstrated that suxamethonium did not modify the onset, duration or reversibility of a clinical dose (0.3 mg/kg) of alcuronium. A low dose of alcuronium (0.2 mg/kg) following suxamethonium provided less relaxation with a longer onset and shorter duration than alcuronium 0.3 mg/kg alone. Thus, the clinical impression that one can use smaller doses of alcuronium satisfactorily after suxamethonium is probably based on the fact that the degree of relaxation needed for surgery may not be as profound as that required for intubation.
